Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Gambacorti-Passerini

Showing results (1-10 of 80) with videos related to

Pageof 8
Sort By:
International Journal of Clinical & Laboratory Research|January 1, 1993
Immunogenicity of fusion proteins. An example of tumor-specific/transformation-related antigensC Gambacorti-Passerini
Cellular and Molecular Life Sciences : CMLS|December 8, 2004
Oncogenic tyrosine kinasesC Gambacorti-Passerini
The New England Journal of Medicine|January 17, 2002
Of nicks and timeC Gambacorti-Passerini
Current Opinion in Oncology|December 1, 1990
Problems, controversies, and perspectives on the clinical use of interleukin-2C Gambacorti-Passerini, P M Sondel
The New England Journal of Medicine|December 7, 1995
The human molecular genetics networkC Gambacorti-Passerini, J Ott, A Bergen
Drugs & Aging|October 1, 1995
The role of the immune system in anti-tumour responses. Potential for drug therapyS Dermime, J Barrett, C Gambacorti-Passerini
Biochemical and Biophysical Research Communications|October 26, 1999
In vitro transcriptional and translational block of the bcl-2 gene operated by peptide nucleic acidL Mologni, P E Nielsen, C Gambacorti-Passerini
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 2018
Practical management of toxicities associated with bosutinib in patients with Philadelphia chromosome-positive chronic myeloid leukemiaH J Khoury, C Gambacorti-Passerini, T H Brümmendorf
International Journal of Cancer|May 15, 1989
Generation and partial characterization of melanoma sublines resistant to lymphokine activated killer (LAK) cells. Relevance to doxorubicin resistanceL Rivoltini, C Gambacorti-Passerini, R Supino, et al.
Cancer Medicine|February 6, 2025
Inflammatory/Immune Adverse Events in Chronic Myeloid Leukemia Patients During Treatment With BosutinibE Agostani, E Tassistro, L Antolini, et al.
Pageof 8

Showing results (1-10 of 80) with videos related to

Sort By:
Pageof 8
International Journal of Clinical & Laboratory Research|January 1, 1993
Immunogenicity of fusion proteins. An example of tumor-specific/transformation-related antigensC Gambacorti-Passerini
Cellular and Molecular Life Sciences : CMLS|December 8, 2004
Oncogenic tyrosine kinasesC Gambacorti-Passerini
The New England Journal of Medicine|January 17, 2002
Of nicks and timeC Gambacorti-Passerini
Current Opinion in Oncology|December 1, 1990
Problems, controversies, and perspectives on the clinical use of interleukin-2C Gambacorti-Passerini, P M Sondel
The New England Journal of Medicine|December 7, 1995
The human molecular genetics networkC Gambacorti-Passerini, J Ott, A Bergen
Drugs & Aging|October 1, 1995
The role of the immune system in anti-tumour responses. Potential for drug therapyS Dermime, J Barrett, C Gambacorti-Passerini
Biochemical and Biophysical Research Communications|October 26, 1999
In vitro transcriptional and translational block of the bcl-2 gene operated by peptide nucleic acidL Mologni, P E Nielsen, C Gambacorti-Passerini
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 2018
Practical management of toxicities associated with bosutinib in patients with Philadelphia chromosome-positive chronic myeloid leukemiaH J Khoury, C Gambacorti-Passerini, T H Brümmendorf
International Journal of Cancer|May 15, 1989
Generation and partial characterization of melanoma sublines resistant to lymphokine activated killer (LAK) cells. Relevance to doxorubicin resistanceL Rivoltini, C Gambacorti-Passerini, R Supino, et al.
Cancer Medicine|February 6, 2025
Inflammatory/Immune Adverse Events in Chronic Myeloid Leukemia Patients During Treatment With BosutinibE Agostani, E Tassistro, L Antolini, et al.
Pageof 8